Marcelo Bigal, M.D., Ph.D.
President and Chief Executive Officer
Marcelo is the President and CEO of Ventus Therapeutics, and has extensive experience in neurology. He has published over 330 peer-reviewed papers in the field of neurology, as well as five books. He has been recognized by the American Academy of Neurology with the Harold G. Wolff Award for excellence in research in neurology.
Marcelo has over 15 years of pharmaceutical experience spanning R&D, medical affairs, and scientific affairs. Prior to Ventus, he was CMO and CSO at Teva Pharmaceuticals, leading the team that developed fremanezumab (Ajovy) for several forms of migraine, as well as deutetrabenazine (Austedo) for the treatment of Huntington's disease and Tardive Dyskinesia, as well as other medicines in neurology, psychiatry, pain, and respiratory diseases approved in the US, Canada, and EU.
Prior to his work in the pharmaceutical industry, Marcelo was a faculty member at the Albert Einstein College of Medicine, Department of Neurology, as well as the Director of Research at New England Center for Headache and Director of Research at Montefiore Headache Center.
Christine Ha
Chief Financial Officer
Christine is the Chief Financial Officer of Ventus Therapeutics. She brings to Ventus more than 15 years of diverse strategic and financial experience within the healthcare sector.
Prior to Ventus, Christine was a Managing Director in the healthcare investment banking group at Morgan Stanley, where she advised biopharmaceutical companies on a broad range of strategic and financing initiatives. Previously, Christine held positions at Credit Suisse, Greenhill & Co, Aisling Capital and HSBC. In her 13 years in investment banking, she executed over $24 billion of transactions, including M&A, collaborations, and financings.
Christine received an MBA with honors from The Wharton School at The University of Pennsylvania and a B.A. with honors in Statistics and a B.S. in Mathematics from The University of Chicago.
Daniel Koerwer
Chief Operating Officer
Daniel is Chief Operating Officer of Ventus Therapeutics. Previously, Daniel was Chief Business Officer at Arrakis Therapeutics and BIND Therapeutics and held positions at Biogen in Corporate Development, Discovery Research, and Commercial Operations. He founded and served as President of Biogen's biosimilars business. Daniel is deeply experienced in building high-growth organizations in the US and abroad, designing and implementing creative strategies to build corporate value, financing innovative companies from inception through IPO, negotiating and managing corporate collaborations, and leading groups of diverse functional experts.
He received a B.S. in Biochemistry from Boston College and an MBA from Harvard University.
Jan Klatt, M.D.
Chief Medical Officer
Jan is the Chief Medical Officer of Ventus Therapeutics. He brings more than 20 years of drug development experience within the pharmaceutical industry to Ventus. In his last role, Jan was the Senior Vice President and Development Unit Head for Neurology & Immunology at Merck KGaA/EMD Serono, overseeing and advancing a diverse portfolio of early- and late-stage compounds across multiple therapeutic areas. Prior to that, Jan spent 16 years in roles of increasing responsibility at Novartis, where he was instrumental in achieving regulatory approvals for first-in-class therapies such as fingolimod in multiple sclerosis, erenumab in migraine, and sacubitril-valsartan in heart failure. Jan obtained his M.D. from Hanover Medical School in Germany.
Dave Schubert
SVP of Regulatory Affairs and Quality
Dave is the SVP of Regulatory Affairs and Quality of Ventus Therapeutics. Dave has over 35 years of experience in regulatory, quality, drug, and process development. He was SVP of Regulatory and Quality at Carmot Therapeutics, responsible for regulatory and quality strategies for its three GLP-1/GIP dual agonist small molecule and peptide products. Carmot was acquired by Roche, where Dave worked most recently. Prior to that, he served as SVP at Chiasma. Dave is a protein chemist by training and was twice the head of CMC in the past, with wide-ranging GXP compliance experience supporting GLP, GCP, and GMP. Dave holds a B.S. from the University of New Hampshire.
Paul Armour
SVP of Finance
Paul is SVP of Finance at Ventus Therapeutics. Paul brings over 16 years of finance experience building and leading Finance & Accounting teams within the healthcare and consumer products sectors. Previously, Paul held leadership roles with Johnson & Johnson, Keurig Dr Pepper, and the late-stage startup Away. During his time with these companies, Paul provided strategic and operational finance leadership across several finance disciplines, including FP&A, M&A, business development, and controllership. Paul holds a B.S. Chemical Engineering from Virginia Tech, an MBA from New York University, and a Master of Accounting from University of North Carolina at Chapel Hill.
Brian Wilson
SVP, Head Human Resources
Brian is Senior Vice President, Head of Human Resources at Ventus Therapeutics. He brings over 15 years of human resources experience building and leading HR teams within the biopharmaceutical and healthcare sectors. Previously, Brian held leadership roles with Alnylam Pharmaceuticals, Merck KGaA (EMD Serono), and Johnson & Johnson. During this time, Brian provided strategic and operational HR leadership across several disciplines, including business partnering, talent management, compensation, organizational strategy, and transformation. He holds an MBA from Boston College.
